These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Neonicotinic analogues: selective antagonists for α4β2 nicotinic acetylcholine receptors. Faundez-Parraguez M; Farias-Rabelo N; Gonzalez-Gutierrez JP; Etcheverry-Berrios A; Alzate-Morales J; Adasme-Carreño F; Varas R; Bermudez I; Iturriaga-Vasquez P Bioorg Med Chem; 2013 May; 21(10):2687-94. PubMed ID: 23561269 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of 5-(11)C-methyl-A-85380 as an imaging agent for PET investigations of brain nicotinic acetylcholine receptors. Iida Y; Ogawa M; Ueda M; Tominaga A; Kawashima H; Magata Y; Nishiyama S; Tsukada H; Mukai T; Saji H J Nucl Med; 2004 May; 45(5):878-84. PubMed ID: 15136639 [TBL] [Abstract][Full Text] [Related]
27. 5-substituted derivatives of 6-halogeno-3-((2-(S)-azetidinyl)methoxy)pyridine and 6-halogeno-3-((2-(S)-pyrrolidinyl)methoxy)pyridine with low picomolar affinity for alpha4beta2 nicotinic acetylcholine receptor and wide range of lipophilicity: potential probes for imaging with positron emission tomography. Zhang Y; Pavlova OA; Chefer SI; Hall AW; Kurian V; Brown LL; Kimes AS; Mukhin AG; Horti AG J Med Chem; 2004 May; 47(10):2453-65. PubMed ID: 15115389 [TBL] [Abstract][Full Text] [Related]
28. Alteration of the in vivo nicotinic receptor density in ADNFLE patients: a PET study. Picard F; Bruel D; Servent D; Saba W; Fruchart-Gaillard C; Schöllhorn-Peyronneau MA; Roumenov D; Brodtkorb E; Zuberi S; Gambardella A; Steinborn B; Hufnagel A; Valette H; Bottlaender M Brain; 2006 Aug; 129(Pt 8):2047-60. PubMed ID: 16815873 [TBL] [Abstract][Full Text] [Related]
29. The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with 2-[(18)F]fluoro-A-85380. Ellis JR; Nathan PJ; Villemagne VL; Mulligan RS; Ellis KA; Tochon-Danguy HJ; Chan JG; O'keefe GJ; Bradley J; Savage G; Rowe CC Synapse; 2009 Sep; 63(9):752-63. PubMed ID: 19484724 [TBL] [Abstract][Full Text] [Related]
30. Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine: a new positron emission tomography ligand for nicotinic receptors. Doll F; Dolci L; Valette H; Hinnen F; Vaufrey F; Guenther I; Fuseau C; Coulon C; Bottlaender M; Crouzel C J Med Chem; 1999 Jun; 42(12):2251-9. PubMed ID: 10377231 [TBL] [Abstract][Full Text] [Related]
31. Physical and virtual screening methods for marine toxins and drug discovery targeting nicotinic acetylcholine receptors. Molgó J; Aráoz R; Benoit E; Iorga BI Expert Opin Drug Discov; 2013 Oct; 8(10):1203-23. PubMed ID: 23919818 [TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of new agents for neuronal nicotinic acetylcholine receptor (nAChRs) imaging. Liu Y; Yu H; Zhao L; Zhang H Nucl Med Biol; 2013 Jan; 40(1):126-34. PubMed ID: 23102538 [TBL] [Abstract][Full Text] [Related]
33. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517 [TBL] [Abstract][Full Text] [Related]
34. Iptakalim as a human nicotinic acetylcholine receptor antagonist. Hu J; Lindenberger K; Hu G; Wang H; Lukas RJ; Wu J J Pharmacol Exp Ther; 2006 Feb; 316(2):914-25. PubMed ID: 16223869 [TBL] [Abstract][Full Text] [Related]
35. Rat nicotinic acetylcholine receptor alpha2beta2 channels: comparison of functional properties with alpha4beta2 channels in Xenopus oocytes. Khiroug SS; Khiroug L; Yakel JL Neuroscience; 2004; 124(4):817-22. PubMed ID: 15026122 [TBL] [Abstract][Full Text] [Related]
36. Differential involvement of α4β2, α7 and α9α10 nicotinic acetylcholine receptors in B lymphocyte activation in vitro. Koval L; Lykhmus O; Zhmak M; Khruschov A; Tsetlin V; Magrini E; Viola A; Chernyavsky A; Qian J; Grando S; Komisarenko S; Skok M Int J Biochem Cell Biol; 2011 Apr; 43(4):516-24. PubMed ID: 21146628 [TBL] [Abstract][Full Text] [Related]
37. High density of nicotinic receptors in the cingulo-insular network. Picard F; Sadaghiani S; Leroy C; Courvoisier DS; Maroy R; Bottlaender M Neuroimage; 2013 Oct; 79():42-51. PubMed ID: 23631995 [TBL] [Abstract][Full Text] [Related]
38. [Nicotine acetylcholine receptors and neuropsychiatric disorders]. Vázquez-Palacios G; Bonilla-Jaime H Rev Neurol; 2004 Dec 16-31; 39(12):1146-60. PubMed ID: 15625635 [TBL] [Abstract][Full Text] [Related]
39. Methadone is a non-competitive antagonist at the α4β2 and α3* nicotinic acetylcholine receptors and an agonist at the α7 nicotinic acetylcholine receptor. Talka R; Salminen O; Tuominen RK Basic Clin Pharmacol Toxicol; 2015 Apr; 116(4):321-8. PubMed ID: 25196810 [TBL] [Abstract][Full Text] [Related]
40. Genetic deletion of the adenosine A(2A) receptor prevents nicotine-induced upregulation of α7, but not α4β2* nicotinic acetylcholine receptor binding in the brain. Metaxas A; Al-Hasani R; Farshim P; Tubby K; Berwick A; Ledent C; Hourani S; Kitchen I; Bailey A Neuropharmacology; 2013 Aug; 71():228-36. PubMed ID: 23583933 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]